| Literature DB >> 25257784 |
Mariana Barbosa1, Patrícia Valentão2, Paula B Andrade3.
Abstract
Marine environment has proven to be a rich source of structurally diverse and complex compounds exhibiting numerous interesting biological effects. Macroalgae are currently being explored as novel and sustainable sources of bioactive compounds for both pharmaceutical and nutraceutical applications. Given the increasing prevalence of different forms of dementia, researchers have been focusing their attention on the discovery and development of new compounds from macroalgae for potential application in neuroprotection. Neuroprotection involves multiple and complex mechanisms, which are deeply related. Therefore, compounds exerting neuroprotective effects through different pathways could present viable approaches in the management of neurodegenerative diseases, such as Alzheimer's and Parkinson's. In fact, several studies had already provided promising insights into the neuroprotective effects of a series of compounds isolated from different macroalgae species. This review will focus on compounds from macroalgae that exhibit neuroprotective effects and their potential application to treat and/or prevent neurodegenerative diseases.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25257784 PMCID: PMC4178484 DOI: 10.3390/md12094934
Source DB: PubMed Journal: Mar Drugs ISSN: 1660-3397 Impact factor: 5.118
Figure 1Microglia-mediated neurotoxicity in Alzheimer’s Disease (AD) and Parkinson’s Disease (PD).
Figure 2Chemical structures of different types of phlorotannins.
Figure 3Chemical structure of triphlorethol A.
Figure 4Inhibition of the formation of advanced glycation end products (AGEs) by some phlorotannins through the scavenging of reactive carbonyl intermediates.
Figure 5Polyphenols involved in neuroprotection mediated by anti-neuroinflammatory and antioxidant mechanisms.
Figure 6Polyphenols with ChE inhibitory activity.
Figure 7Chemical structure of caulerpin.
Figure 8Chemical structure of racemosin A (a) and racemosin B (b).
Figure 9Schematic representation of the biosynthesis of the major subclasses of terpenes. Monoterpenes (C10), sesquiterpenes (C15) and diterpenes (C20) are derived from the corresponding intermediates, by sequential head-to-tail addition of C5 units. Triterpenes (C30) result from two C15 units linked head-to-head and tetraterpenes (C40) are formed from two C20 units, also joined head-to-head.
Figure 10Chemical structure of sargachromenol.
Figure 11Chemical structure of sargaquinoic acid.
Figure 12Chemical structure of pacifenol (a), epitaondiol (b) and stypotriol triacetate (c).
Figure 13Chemical structure of (5E,10Z)-6,10,14-trimethylpentadeca-5,10-dien-2,12-dione (a) and (5E,9E,13E)-6,10,14-trimethylpentadeca-5,9,13-trien-2,12-dione (b).
Figure 14Chemical structure of caulerpenyne.
Figure 15Chemical structure of fucoxanthin.
Figure 16Chemical structure of astaxanthin (AST).
Figure 17Chemical structure of pheophytin A.
Figure 18Chemical structure of fucosterol (a) and cholesterol (b).
Figure 19Chemical structure of fucoidan from Fucus evanescens C. Agardh (a) and from F. vesiculosus and Ascophyllum nodosum (Linnaeus) Le Jolis (b).
Figure 20Chemical structure of κ-carrageenan.
Figure 21Chemical structure of EPA (a) and DHA (b).
Figure 22Chemical structure of floridoside.
Neuroprotective compounds from macroalgae and possible mechanisms involved.
| Class | Compound | Neuroprotective Effects | References | |
|---|---|---|---|---|
| Phloroglucinol | Suppression of the overproduction of intracellular ROS, decrease of intracellular Ca2+ levels and reduction of apoptosis | [ | ||
| Dieckol | Inhibitory activity against AChE | [ | ||
| Reduction of the expression and release of •NO, PGE2, IL-1β and TNF-α in microglial cells | [ | |||
| Suppression of the overproduction of intracellular ROS, decrease of intracellular Ca2+ levels and reduction of apoptosis | [ | |||
| Phlorofucofuroeckol | Inhibitory activity against AChE | [ | ||
| Phlorofucofuroeckol A | Inhibitory activity against AChE and BuChE | [ | ||
| Suppression of intracellular ROS generation and decrease of Ca2+ levels | [ | |||
| Eckol | Inhibitory activity against AChE | [ | ||
| Suppression of the overproduction of intracellular ROS, decrease of intracellular Ca2+ levels and reduction of apoptosis | [ | |||
| 2-Phloroeckol | Inhibitory activity against AChE | [ | ||
| 7-Phloroeckol | Inhibitory activity against AChE | [ | ||
| Suppression of intracellular ROS generation and decrease of Ca2+ levels | [ | |||
| Eckstolonol | Inhibitory activity against AChE and BuChE | [ | ||
| Suppression of the overproduction of intracellular ROS, decrease of intracellular Ca2+ levels and reduction of apoptosis | [ | |||
| 6,6′-Bieckol | Potent inhibitory activity against AChE (non-competitive inhibition type) | [ | ||
| DPHC | Moderate inhibitory activity against BuChE | [ | ||
| Antioxidant mechanisms and control of intracellular Ca2+ levels | [ | |||
| Triphlorethol A | Suppression of the overproduction of intracellular ROS, decrease of intracellular Ca2+ levels and reduction of apoptosis | [ | ||
| Fucophlorethol A | Scavenging of reactive carbonyls, inhibiting the formation of AGEs | [ | ||
| Tetrafucol A | Scavenging of reactive carbonyls, inhibiting the formation of AGEs | [ | ||
| Trifucodiphlorethol A | Scavenging of reactive carbonyls, inhibiting the formation of AGEs | [ | ||
| Dibenzo [1,4] dioxine-2,4,7,9-tetraol | Inhibitory activity against AChE | [ | ||
| Caulerpin | Antioxidant properties | [ | ||
| Moderate/weak attenuation of Aβ-induced SH-SY5Y cell damage (unknown mechanism) | [ | |||
| Racemosin A | Strong attenuation of Aβ-induced SH-SY5Y cell damage (unknown mechanism) | [ | ||
| Racemosin B | Moderate/weak attenuation of the Aβ-induced SH-SY5Y cell damage (unknown mechanism) | [ | ||
| Sargachromenol | Promotion of NGF–dependent neurogenesis by stabilization of the microtubule assembling and extension of neuritis
| [ | ||
| Moderate inhibitory activity against AChE | [ | |||
| Sargaquinoic acid | Enhancement of neuritis outgrowth
| [ | ||
| Antioxidant properties | [ | |||
| Potent inhibitory activity against BuChE and moderate inhibitory activity against AChE | [ | |||
| Epitaondiol | Inhibition of PLA2 and COX pathway | [ | ||
| Stypotriol triacetate | ||||
| Pacifenol | Inhibition of PLA2 and COX pathway | [ | ||
| (5 | Moderate inhibitory activity against AChE and BuChE | [ | ||
| (5 | ||||
| Caulerpenyne | Inhibitory activity against LOX | [ | ||
| Fucoxanthin | Attenuation of neuronal cell damage through scavenging activity | [ | ||
| Inhibition of intracellular ROS formation, DNA damage, and apoptosis induced by H2O2 | [ | |||
| Suppression of inflammation and oxidative damage in microglial cells | [ | |||
| AST | Suppression of expression and formation of •NO, iNOS and COX-2 | [ | ||
| Suppression of intracellular ROS generation, mitochondrial dysfunctions and p38 MAPK pathway | [ | |||
| Antioxidant properties | [ | |||
| Reduction of the expression of IL-6
| [ | |||
| Suppression of MPP+/MPTP-induced mitochondrial dysfunction and ROS production
| [ | |||
| Suppression of ROS production and inhibition of Sp1/NR1 signaling pathway | [ | |||
| Pheophytin A | Enhancement of neuritis outgrowth
| [ | ||
| Potent inhibitory activity against LOX enzymes | [ | |||
| Fucosterol | Moderate inhibitory activity against BuChE | [ | ||
| Inhibitory activity against AChE and BuChE | [ | |||
| C-PC | Scavenge of numerous radicals and inhibition of lipid peroxidation, preventing oxidative damage | [ | ||
| Protection against iron-induced SH-SY5Y toxicity through the increase of cellular antioxidant enzymes (GPx, GR, GPx-Se) and GSH levels | [ | |||
| Protection of hippocampus neurons induced by global cerebral ischemia/reperfusion injury through the reduction of ROS levels and possible inhibition of acute microglia activation | [ | |||
| Fucoidan | Suppression of ROS generation and activation of caspase-9 and caspase-3 | [ | ||
| Antioxidant properties | [ | |||
| Activation of PI3K/Akt survival pathway | [ | |||
| κ-carrageenan | Inhibition of the viability and content of •NO, TNF-α and IL-10 released by LPS-activated microglia cells | [ | ||
| EPA | Moderate inhibitory activity against AChE | [ | ||
| Anti-inflammatory activity of EPA-derived products (resolvin E1, and 5- and 18-hydroxy-EPA) | [ | |||
| DHA | Inhibitory activity against AChE | [ | ||
| Promotion of neuronal survival by positive modulation of Akt | [ | |||
| Enhancement of neuritis growth and synaptogenesis by DHA ethanolamide metabolites | [ | |||
| DHA-derived mediator (NPD 1) promotes cell survival presumably through the up-regulation of Bcl-2 and Bcl-xL, down-regulation of Bax and Bad, suppression of oxidative stress-induced caspase-3 activation and IL-1-stimulated expression of COX-2 | [ | |||
| Floridoside | Suppression of pro-inflammatory responses in microglia through the inhibition of the production of •NO and ROS and blockage of MAPK pathway | [ | ||